Literature DB >> 23117656

Galectin-3 mediates aldosterone-induced vascular fibrosis.

Laurent Calvier1, Maria Miana, Pascal Reboul, Victoria Cachofeiro, Ernesto Martinez-Martinez, Rudolf A de Boer, Françoise Poirier, Patrick Lacolley, Faiez Zannad, Patrick Rossignol, Natalia López-Andrés.   

Abstract

OBJECTIVE: Aldosterone (Aldo) is involved in arterial stiffness and heart failure, but the mechanisms have remained unclear. Galectin-3 (Gal-3), a β-galactoside-binding lectin, plays an important role in inflammation, fibrosis, and heart failure. We investigated here whether Gal-3 is involved in Aldo-induced vascular fibrosis. METHODS AND
RESULTS: In rat vascular smooth muscle cells Gal-3 overexpression enhanced specifically collagen type I synthesis. Moreover Gal-3 inhibition by modified citrus pectin or small interfering RNA blocked Aldo-induced collagen type I synthesis. Rats were treated with Aldo-salt combined with spironolactone or modified citrus pectin for 3 weeks. Hypertensive Aldo-treated rats presented vascular hypertrophy, inflammation, fibrosis, and increased aortic Gal-3 expression. Spironolactone or modified citrus pectin treatment reversed all the above effects. Wild-type and Gal-3 knock-out mice were treated with Aldo for 6 hours or 3 weeks. Aldo increased aortic Gal-3 expression, inflammation, and collagen type I in wild-type mice at both the short- and the long-term, whereas no changes occurred in Gal-3 knock-out mice.
CONCLUSIONS: Our data indicate that Gal-3 is required for inflammatory and fibrotic responses to Aldo in vascular smooth muscle cells in vitro and in vivo, suggesting a key role for Gal-3 in vascular fibrosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23117656     DOI: 10.1161/ATVBAHA.112.300569

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  115 in total

1.  Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure.

Authors:  Tariq Ahmad; Mona Fiuzat; Benjamin Neely; Megan L Neely; Michael J Pencina; William E Kraus; Faiez Zannad; David J Whellan; Mark P Donahue; Ileana L Piña; Kirkwood F Adams; Dalane W Kitzman; Christopher M O'Connor; G Michael Felker
Journal:  JACC Heart Fail       Date:  2014-06       Impact factor: 12.035

Review 2.  Biomarkers for risk prediction in acute decompensated heart failure.

Authors:  A Rogier van der Velde; Wouter C Meijers; Rudolf A de Boer
Journal:  Curr Heart Fail Rep       Date:  2014-09

3.  Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study.

Authors:  Lori B Daniels; Paul Clopton; Gail A Laughlin; Alan S Maisel; Elizabeth Barrett-Connor
Journal:  Am Heart J       Date:  2014-02-18       Impact factor: 4.749

Review 4.  Circulating biomarkers in patients with heart failure and preserved ejection fraction.

Authors:  Eileen O'Meara; Simon de Denus; Jean-Lucien Rouleau; Akshay Desai
Journal:  Curr Heart Fail Rep       Date:  2013-12

5.  Galectin 3 and incident atrial fibrillation in the community.

Authors:  Jennifer E Ho; Xiaoyan Yin; Daniel Levy; Ramachandran S Vasan; Jared W Magnani; Patrick T Ellinor; David D McManus; Steven A Lubitz; Martin G Larson; Emelia J Benjamin
Journal:  Am Heart J       Date:  2014-03-01       Impact factor: 4.749

6.  Letter to the Editor: Not all modified citrus pectins are the same: size does matter.

Authors:  Isaac Eliaz
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-05-01       Impact factor: 4.733

7.  The potential role of leptin in the vascular remodeling associated with obesity.

Authors:  E Martínez-Martínez; M Miana; R Jurado-López; M V Bartolomé; F V Souza Neto; M Salaices; N López-Andrés; V Cachofeiro
Journal:  Int J Obes (Lond)       Date:  2014-03-03       Impact factor: 5.095

8.  Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease.

Authors:  Casey M Rebholz; Elizabeth Selvin; Menglu Liang; Christie M Ballantyne; Ron C Hoogeveen; David Aguilar; John W McEvoy; Morgan E Grams; Josef Coresh
Journal:  Kidney Int       Date:  2017-08-31       Impact factor: 10.612

Review 9.  The Current and Potential Clinical Relevance of Heart Failure Biomarkers.

Authors:  Parul U Gandhi; Jeffrey M Testani; Tariq Ahmad
Journal:  Curr Heart Fail Rep       Date:  2015-10

Review 10.  New Targets in the Drug Treatment of Heart Failure.

Authors:  James A Iwaz; Elizabeth Lee; Hermineh Aramin; Danilo Romero; Navaid Iqbal; Matt Kawahara; Fatima Khusro; Brian Knight; Minal V Patel; Sumita Sharma; Alan S Maisel
Journal:  Drugs       Date:  2016-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.